Ordinary Adjustment | Solactive China Healthcare Disruption Index | Effective Date 2nd December 2024
Solactive China Healthcare Disruption Index:
In the ordinary adjustment, the following composition will be implemented effective open 2nd December 2024:
| HUTCHMED CHINA LTD |
| ALIBABA HEALTH INFORMATION TECHNOLOGY LTD |
| SIHUAN PHARMACEUTICAL HLDGS GRP ORD |
| GRAND PHARMACEUTICAL GROUP LTD |
| CHINA MEDICAL SYSTEM HOLDINGS LTD |
| CSPC PHARMACEUTICAL GROUP LTD |
| SINO BIOPHARMACEUTICAL LTD ORD |
| SHANGHAI FUDAN-ZHANGJIANG BIO- |
| LIVZON PHARMACEUTICAL GROUP INC |
| GENSCRIPT BIOTECH CORP |
| YICHANG HEC CHANGJIANG PHA-H |
| INNOVENT BIOLOGICS INC |
| SHANGHAI JUNSHI BIOSCIENCES CO LTD |
| SIMCERE PHARMACEUTICAL GROUP |
| LEPU BIOPHARMA CO LTD-H |
| KEYMED BIOSCIENCES INC |
| LUYE PHARMA GROUP LTD |
| SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD |
| SHANGHAI MICROPORT MEDBOT GR |
| WUXI BIOLOGICS CAYMAN INC |
| WUXI APPTEC CO LTD |
| SHANGHAI PHARMACEUTICALS HOLDING CO LTD-H |
| CHINA RESOURCES PHARMACEUTICAL |
| HANSOH PHARMACEUTICAL GROUP CO |
| PHARMARON BEIJING CO LTD-H |
| AIM VACCINE CO LTD |
| SKB BIO-B ORD H |
| ZAI LAB LTD |
| AKESO INC |
| ALPHAMAB ONCOLOGY |
| REMEGEN CO LTD-H |
| KANGJI MEDICAL HOLDINGS LTD |